Drug Type Monoclonal antibody |
Synonyms OGD-201 |
Target |
Action inhibitors |
Mechanism GD2 inhibitors(Disialoganglioside GD2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| High Risk Neuroblastoma | Preclinical | France | 01 Aug 2026 |






